Anna Puła

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Ibrutinib and idelalisib, B-cell receptor (BCR) signaling pathway inhibitors, have been recently approved for use against relapsed/refractory chronic lymphocytic leukemia (CLL). To assess the efficacy and safety of BCR pathway inhibitors in relapsed/refractory CLL, we conducted a systematic review and meta-analysis of five randomized controlled trials (1866(More)
UNLABELLED The aim of the study was to assess patients' awareness of the prevention and treatment of colorectal cancer. MATERIAL AND METHODS Patients diagnosed with colorectal cancer, hospitalised at the Department of General and Colorectal Surgery of the Medical University in Łódź during the period from January 2015 to April 2015, were asked to complete(More)
  • 1